Becton, Dickinson shares are trading higher after the company announced it received FDA510(k) clearance for the updated BD Alaris Infusion System. Also, Raymond James upgraded the stock from Market Perform to Outperform with a $305 price target.
Portfolio Pulse from Benzinga Newsdesk
Becton, Dickinson and Company (BDX) shares are trading higher after the company received FDA510(k) clearance for the updated BD Alaris Infusion System. Raymond James upgraded the stock from Market Perform to Outperform with a $305 price target.
July 24, 2023 | 12:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Becton, Dickinson and Company's stock is likely to rise in the short term due to FDA clearance for its updated infusion system and an upgrade from Raymond James.
The FDA clearance for Becton, Dickinson and Company's updated BD Alaris Infusion System is a positive development for the company, indicating regulatory approval for its product. This is likely to boost investor confidence in the company's product pipeline and future revenue potential. Additionally, the upgrade from Raymond James from Market Perform to Outperform, along with a $305 price target, suggests that analysts see strong potential in the company's stock, which could drive further buying interest.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100